^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Regimen:BR
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/19/2021
    Excerpt:
    BR ± idelalisib or ibrutinib is included as an option for relapsed/refractory therapy, regardless of patient's age or comorbidities.